Disruptive behavior, hyperactivity, and learning disabilities in children with Tourette's syndrome.
As in many other areas of science, improvements in research methodologies lead the way to powerful new understanding of disorders and their treatment. Great strides have been made in defining the phenomenology of TS and its relationship to other disorders. However, we have not yet reached a true consensus and developed treatment strategies based on that consensus. Clearly much research needs to be done. Identifying the putative gene for TS would greatly accelerate this process.
Walkup
J T
JT
Division of Child and Adolescent Psychiatry, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287.
Scahill
L D
LD
Riddle
M A
MA
D000293:Adolescent; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D002648:Child; D002653:Child Behavior Disorders / Q000209:etiology / Q000523:psychology; D003000:Clonidine / Q000627:therapeutic use; D015897:Comorbidity; D003913:Dextroamphetamine / Q000627:therapeutic use; D016316:Guanfacine / Q000627:therapeutic use; D006801:Humans; D007859:Learning Disabilities / Q000209:etiology / Q000523:psychology; D008774:Methylphenidate / Q000627:therapeutic use; D010389:Pemoline / Q000627:therapeutic use; D012642:Selegiline / Q000627:therapeutic use; D005879:Tourette Syndrome / Q000150:complications* / Q000453:epidemiology / Q000523:psychology
D000929:Antidepressive Agents, Tricyclic; D008774:Methylphenidate; D012642:Selegiline; D016316:Guanfacine; D010389:Pemoline; D003000:Clonidine; D003913:Dextroamphetamine